MedMatrix Rx
340B Program Reforms and Legal Challenges
Recent developments in the 340B program reveal ongoing challenges and shifts in policy. The Health Resources and Services Administration (HRSA) has approved 10 drugmakers for a revised 340B rebate model pilot, transitioning from upfront discounts to post-sale rebates for certain drugs set to begin in 2027. This change is met with scrutiny, as an ASPE report criticizes the program for prioritizing financial incentives over patient care and raises concerns about market consolidation. In response, the American Hospital Association (AHA) is advocating for a permanent ban on rebate models, citing administrative burdens. Meanwhile, 340B hospitals are reporting lower charity care spending compared to their non-340B counterparts, prompting questions about the program’s effectiveness in supporting patient needs. As these developments unfold, the implications for covered entities and their ability to deliver care remain significant.
EXECUTIVE SUMMARY
01
HRSA Approves 340B Rebate Pilot Participants.
HRSA approves 10 drugmakers for a revised 340B rebate model pilot, shifting from upfront discounts to post-sale rebates for certain drugs in 2027.
HRSA approves 10 drugmakers for a revised 340B rebate model pilot, shifting from upfront discounts to post-sale rebates for certain drugs in 2027.
Source: Becker’s Hospital Review
02
ASPE Report Criticizes 340B Incentive Misalignment.
ASPE report criticizes the 340B program for prioritizing financial spread over patient needs and raises concerns about market consolidation.
ASPE report criticizes the 340B program for prioritizing financial spread over patient needs and raises concerns about market consolidation.
Source: ASPE
03
AHA Seeks Permanent 340B Rebate Ban.
The American Hospital Association urges Congress to permanently ban rebate models in the 340B program, citing administrative burdens.
The American Hospital Association urges Congress to permanently ban rebate models in the 340B program, citing administrative burdens.
Source: Becker’s Hospital Review
04
CMS Opens 340B Data Repository.
CMS launches a Medicare Part D Claims Data 340B Repository for voluntary submissions, with mandatory compliance expected by 2027.
CMS launches a Medicare Part D Claims Data 340B Repository for voluntary submissions, with mandatory compliance expected by 2027.
Source: Becker’s Hospital Review
05
340B Hospitals Report Less Charity Care.
340B hospitals report lower charity care spending compared to non-340B hospitals, raising questions about the program’s impact on patient care.
340B hospitals report lower charity care spending compared to non-340B hospitals, raising questions about the program’s impact on patient care.
Source: Medical Daily
06
PharmaForce Launches 340B Rebate Solution.
PharmaForce unveils a connected 340B rebate and Maximum Fair Price solution to streamline claim submissions and payment reconciliation.
PharmaForce unveils a connected 340B rebate and Maximum Fair Price solution to streamline claim submissions and payment reconciliation.
Source: Business Wire
07
Plenful’s Rebate Intelligence Solution Debuts.
Plenful introduces an AI-driven rebate intelligence solution to automate rebate submissions under HRSA’s revised 340B model.
Plenful introduces an AI-driven rebate intelligence solution to automate rebate submissions under HRSA’s revised 340B model.
Source: Becker’s Hospital Review
08
340B Rebate Model Pilot Faces Legal Scrutiny.
Legal challenges continue against the 340B rebate model pilot, with appeals and motions impacting its implementation.
Legal challenges continue against the 340B rebate model pilot, with appeals and motions impacting its implementation.
Source: Newsbreak
EXECUTIVE SUMMARY — KEY TAKEAWAYS
Most important 340B implication. The implications of these developments for covered entities are significant. The shift to a post-sale rebate model may alter the financial situation for hospitals participating in the 340B program, impacting their revenue streams and ability to provide charity care. As the AHA pushes for a permanent ban on rebate models, covered entities may face increased administrative burdens and uncertainty regarding their financial incentives. Furthermore, the findings from the ASPE report regarding the misalignment of incentives could lead to heightened scrutiny of the program, prompting covered entities to reassess their strategies for patient care and financial sustainability. The ongoing legal challenges surrounding the rebate model pilot add another layer of complexity, as outcomes could reshape the operational framework for 340B hospitals and their interactions with pharmaceutical manufacturers.
Emerging risks.
- Hospitals may face reduced revenue from 340B drugs due to CMS’s proposed payment cuts.
- Legal challenges could delay or alter the implementation of the 340B rebate model pilot.
- Potential administrative burdens from new reporting requirements could strain hospital resources.
- Changes in 340B program incentives might lead to reduced access to certain drugs for patients.
- The shift to a rebate model could complicate financial planning for covered entities.
Emerging opportunities.
- Hospitals can use new technology solutions like PharmaForce’s to streamline rebate processes.
- The proposed CMS changes may encourage hospitals to focus more on patient outcomes rather than financial spread.
- Hospitals could explore alternative revenue streams to offset potential 340B revenue losses.
- Engagement with policymakers could shape future 340B program reforms to better meet hospital needs.
- Increased transparency in 340B transactions could improve trust and accountability in the program.
Key actions for providers.
- Hospitals should assess the financial impact of CMS’s proposed 340B payment changes on their operations.
- Covered entities need to prepare for mandatory data submissions to the 340B repository by 2027.
- Stakeholders should engage in advocacy efforts to influence 340B program reforms.
- Hospitals must evaluate their charity care policies in light of recent reports and criticisms.
- Entities should consider adopting new technologies to manage 340B rebate processes efficiently.
TOP STORIES
HRSA Approves 340B Rebate Pilot Participants.
Becker’s Hospital Review · October 2, 2026
- HRSA approves 10 drugmakers for a revised 340B rebate model pilot.
- The pilot shifts from upfront discounts to post-sale rebates for certain drugs.
- The program is set to launch on January 1, 2027.
FEDERAL POLICY & REGULATORY DEVELOPMENTS
ASPE Report Criticizes 340B Incentive Misalignment.
ASPE · October 8, 2026
- ASPE report criticizes 340B for prioritizing financial spread over patient needs.
- The program’s expansion has led to increased participation and costs.
- CMS’s proposed rule aims to align payments with acquisition costs.
AHA Seeks Permanent 340B Rebate Ban.
Becker’s Hospital Review · September 25, 2026
- AHA urges Congress to permanently ban rebate models in the 340B program.
- The SECURE 340B Act includes protections and new requirements.
- AHA warns of administrative and financial burdens on hospitals.
340B Hospitals Report Less Charity Care.
Medical Daily · September 28, 2026
- 340B hospitals spend less on charity care compared to non-340B hospitals.
- The report raises questions about the program’s impact on patient care.
- The hospital industry disputes the report’s framing.
340B PROGRAM DEVELOPMENTS
PharmaForce Launches 340B Rebate Solution.
Business Wire · October 6, 2026
- PharmaForce unveils a connected 340B rebate and Maximum Fair Price solution.
- The solution streamlines claim submissions and payment reconciliation.
- It integrates with existing platforms to determine 340B eligibility.
Plenful’s Rebate Intelligence Solution Debuts.
Becker’s Hospital Review · October 6, 2026
- Plenful introduces an AI-driven rebate intelligence solution.
- The solution automates rebate submissions under HRSA’s revised 340B model.
- It reduces the manual burden on 340B teams.
LITIGATION & ENFORCEMENT WATCH
| Court | Matter | Date |
|---|---|---|
| D.D.C. | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA v. KENNEDY JR. — Complaint against center for medicare and medicaid innovation, centers for medicare & medicaid services, robert F. kennedy jr., mehmet oz, abe sutton, united states department of health and human services. Case filed October 7, 2026. [source] | October 7, 2026 |
| Bankr. D. Del. | Akorn Holding Company LLC — Motion to Approve Compromise under Rule 9019 Motion of the Chapter 7 Trustee for Entry of an Order Approving the Settlement and Compromise of Claims Against p&l Development, LLC Filed by George L. Miller. Case filed February 23, 2023. [source] | October 6, 2026 |
| D.N.H. | Mary Hitchcock Memorial Hospital v. Eli Lilly and Company — Amended Complaint. Case filed July 27, 2026. [source] | September 30, 2026 |
| 8th Cir. | Astrazeneca Pharmaceuticals, LP v. Marty Jackley — Reply to response to petition for initial hearing en banc. Case filed August 11, 2026. [source] | September 25, 2026 |
| 8th Cir. | Pharm. Res. & Mfr. of America v. Marty Jackley — Motion to file a reply to response,. Case filed August 25, 2026. [source] | September 25, 2026 |
| N.D. Ill. | Novartis Pharmaceuticals Corporation v. Raoul, in his official capacity as Attorney General for the State of Illinois — Order signed by the Honorable Edmond E. Chang. For the reasons stated in the Order, the motion for expedited discovery 34 is denied. Case filed August 7, 2026. [source] | September 24, 2026 |
| E.D. Mo. | AbbVie Inc. v. Hanaway — Memorandum and order: Accordingly, the Court grants Intervenors’ motion to intervene. see order for details. Case filed July 22, 2024. [source] | September 24, 2026 |
| E.D. Mich. | Henry Ford Hospital v. CVS Health Corporation — Reply to Response to Motion. Case filed July 16, 2026. [source] | September 23, 2026 |
MANUFACTURER WATCH
| Manufacturer | Action | Date |
|---|---|---|
| AbbVie, Amgen, Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Merck, Pfizer, Teva | Approved for 340B rebate model pilot, shifting to post-sale rebates for certain drugs. [source] | October 2, 2026 |
WHAT TO WATCH NEXT
- CMS’s proposed 340B payment reform set to take effect in 2027, pending final approval. [source]
- HRSA’s revised 340B rebate model pilot launching January 1, 2027. [source]
- Ongoing legal challenges to the 340B rebate model pilot and potential impacts. [source]
End of briefing.
This briefing is provided for informational purposes only and does not constitute legal, regulatory, financial, or compliance advice. Automated summarization may contain errors or omissions, and source materials may change after publication. Recipients should independently verify all information against the cited primary sources before relying on it.
© 2026 MedMatrix Rx. All rights reserved.